A Phase I, Randomised, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RB042 Administered Via Inhalation to Healthy Adult Volunteers and Healthy Adult Smokers
Latest Information Update: 05 Feb 2026
At a glance
- Drugs RB 042 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; First in man
- Sponsors RAGE Biotech
Most Recent Events
- 02 Feb 2026 Planned initiation date changed from 1 Dec 2025 to 22 Jan 2026.
- 02 Feb 2026 Status changed from not yet recruiting to recruiting.
- 26 Dec 2025 New trial record